Three benchmarks were performed during the period 2017–2018 pertaining to specific cancer types grouped in three activity domains: solid tumors (benchmark 2017/1), hematological malignancies (benchmark 2017/2), and BRCA1/2 (benchmark 2018/1). Here, BRCA1 is linked to hematologic disorder.